Actavis acquires remaining stake in Turkish pharmaceutical company Fako
Advertisement
Actavis Group announced that it has acquired the remaining 11% stake in the Turkish generic pharmaceuticals company Fako for US$20.4 million. Fako now becomes a wholly-owned subsidiary of the Actavis Group.
Actavis acquired an 89% stake in Fako in December 2003 for an initial purchase price of US$63 million. In addition, Actavis agreed to provide Fako with up to US$15 million to assist its funding requirements.
Fako is Turkey's fifth-largest generic pharmaceutical company, specialising in the development, production and sales of pharmaceuticals. It has a total workforce of around 1,200 employees. Along with its headquarters in Istanbul, the company has 10 sales offices throughout Turkey. Fako also develops and produces active pharmaceutical ingredients.
Most read news
Other news from the department business & finance
These products might interest you

AZURA Purifier + LH 2.1 by KNAUER
Preparative Liquid Chromatography - New platform for more throughput
Save time and improve reproducibility during purification

Pharmaceutical Substances by Thieme Verlag
Look up Industrial Syntheses of 2,600 APIs
Your tool for Syntheses, Patents and Applications – Pharmaceutical Substances

Get the chemical industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Univar successfully closes Quaron acquisition
SCHWARZ PHARMA secures future neurology projects
Great Lakes and Teijin Chemicals intend to combine their global brominated carbonate oligomer activities

SAMPLES | Laboratory information management systems | qualitype
Europe at the cutting edge of nanotechnology development
High-resolution measurement of photocurrents

Joining metals without welding - Prototype for new connection technology
Great Lakes Chemical Eliminates Price Protection For Flame Retardants And Brominated Performance Products

Cooperation with Namibia underway - Natural resources as a basis for new materials
Expanded compounding activities: Polymer Group aims for the 200,000 tonnes mark - Based on its record of continuous growth, the Polymer Group s aiming for an overall compounding volume of 200,000 MT/a for the first time ever in 2009
Asset swap between Wintershall and Statoil completed - Oil and gas production in Norway rises from around 3,000 barrels to almost 40,000 barrels of oil equivalent (boe) per day
